


COVID-19 Monoclonal Antibody Order Workflow


8/27/2021

Objective: When a patient tests positive for COVID-19 and meets the requirements for Monoclonal Antibody treatment, the Provider will be able to place orders for medication and scheduling request, as well as associate diagnosis codes within the COVID-19 Monoclonal Antibody Treatment SmartSet.

1. In an Encounter open the **COVID-19 Monoclonal Antibody Treatment SmartSet**.



2. In the Scheduling Request, fill in the date the patient should receive treatment or the last date they can be scheduled for the treatment. The CSS that will schedule the patient sees this date on their workqueue.



COVID-19 Monoclonal Antibody Order Workflow

3. The Diagnoses section provides the criteria the patient must reach to qualify for treatment. It will filter to show age-specific criteria. Below the description **check off** any applicable **diagnoses** for the patient.

You can also add diagnoses by pulling them from the patient's problem list. At the bottom of SmartSet click **Associate**. Click **Problems** and then associate it to both the injection and scheduling request.

▼ Diagnoses

▼ Diagnosis for Monoclonal Antibody Treatment for COVID

Age 55-64 may qualify for monoclonal antibody treatment if they have certain age based risk factors.
Select appropriate diagnosis from problem list (preferred) or below.

- COVID+ and symptoms 10 days or less
- Diabetes
- Obesity with BMI > 30
- A condition that weakens the immune system, or a medication that weakens the immune system
- Heart or circulatory disease
- High blood pressure
- COPD, asthma, or other long term lung disease
- Dependence on regular use of medical device like ventilator or feeding tube
- HHS Combat Covid website :: How do I know if I'm high risk?

- COVID-19 virus infection [U07.1]
- Diabetes mellitus type 1 (HCC) [E10.9]
- Diabetes mellitus, type 2 (HCC) [E11.9]
- Chronic kidney disease (CKD) [N18.9]
- Immunocompromised (HCC) [D84.9]
- Immunocompromised state due to drug therapy (HCC) [D84.821, Z79.899]
- Heart failure (HCC) [I50.9]
- Cardiomyopathy (HCC) [I42.9]
- Heart disease [I51.9]

Here is a [link](#) to the HHS Combat Covid website

4. The SmartSet includes the EUA Patient Information. This will show on the AVS and also in MyHealth.

5. Additional SmartSet Orders can be added if necessary

▼ Patient Instructions


▼ Patient Instructions

EUA Patient Information

▼ Additional SmartSet Orders

COVID-19 Monoclonal Antibody Order Workflow

6. Sign the SmartSet and let the patient know someone will contact them to schedule their appointment.
7. The SmartSet appends the **Patient Consent** to your note. This states you have counseled the patient on alternatives to receiving the drug and it is an unapproved drug authorized for use under Emergency Use Authorization.
8. Fill in the note by clicking F2, the default choice will be Yes.



The screenshot shows the Epic My Note editor interface. At the top, it says "My Note" with a red circle containing the number "7" and a "Tag" button. Below the title is a rich text editor toolbar with various icons for bold, italic, underline, strikethrough, text color, font size (set to 100%), cut, copy, paste, list, indent, link, unlink, and insert. Below the toolbar is a text area containing the following text:

I have counseled the patient on the following:

- Alternatives to receiving REGEN-COV (casirivimab and imdevimab): {YES/NO:19832::"yes"}
- REGEN-COV (casirivimab and imdevimab) is an unapproved drug that is authorized for use under Emergency Use Authorization (EUA): {YES/NO:19832::"yes"}
- Full medication fact sheet is provided prior to medication administration and internet link to fact sheet is provided on the AVS for this visit.